Paige has launched a new artificial intelligence (AI)-based digital assay to identify and diagnose microsatellite instability (MSI) status in colon cancers.

Part of the company’s Colon Suite, the new Paige Colon MSI can run on whole slide images of haematoxylin and eosin-stained slides alone.

It enables a slide-level classification of MSI status in colon cancer samples.

Paige biomarker development medical director Dr Joe Oakley said: “Paige Colon MSI is another example of how the company is innovating to empower pathologists, transform pathology and improve the lives of patients with cancer.

“We used the most advanced machine learning methods available on the most robust dataset in the industry to improve AI detection of MSI in colon cancer.

“We hope to demonstrate that this assay will offer laboratories and healthcare systems a chance to reduce MSI screening costs and accelerate their workflows.”

Pathologists using the new assay can benefit from additional insight into identifying patients who could benefit from definitive MSI/MMR testing, which is crucial to detect common hereditary cancer syndrome and provide immuno-oncology therapy.

Paige has specifically designed the system for optimal negative predictive value.

It supports the immediate generation of AI results from digitised stained sections, thereby reducing diagnostic turnaround times.

Paige became the first company to secure approval from the US Food and Drug Administration for a clinical AI application in digital pathology when it received de novo marketing authorisation for its Paige Prostate Detect in September 2021.